Press Releases

All Releases
View Summary Five Prime Therapeutics Doses First Cohort of Subjects in Phase 1 Study of FPA008
Thursday, October 31, 2013
PDF 10.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call on November 12
Tuesday, October 29, 2013
PDF 6.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Appoints Aron Knickerbocker to Its Board of Directors and Marc Belsky to Chief Financial Officer
Wednesday, October 23, 2013
PDF 8.6 KB Add to Briefcase
View Summary Five Prime Announces the Exercise of the Underwriters' Over-Allotment Option
Thursday, September 26, 2013
PDF 16.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Closing of Initial Public Offering
Monday, September 23, 2013
PDF 16.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Pricing of Initial Public Offering
Tuesday, September 17, 2013
PDF 17.0 KB Add to Briefcase
View Summary UCB AND FIVE PRIME THERAPEUTICS ANNOUNCE STRATEGIC DISCOVERY COLLABORATION
Tuesday, March 19, 2013
PDF 7.1 KB Add to Briefcase
View Summary FIVE PRIME THERAPEUTICS ANNOUNCES ADDITION OF JULIE HAMBLETON, M.D., AS SENIOR VICE PRESIDENT AND CHIEF MEDICAL OFFICER
Monday, December 3, 2012
PDF 7.7 KB Add to Briefcase
View Summary Lonza and Biowa Sign License Agreements with FivePrime Therapeutics for Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Development
Wednesday, June 13, 2012
PDF 12.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces that Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand Trap
Monday, June 4, 2012
PDF 7.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces the Promotion of Aron Knickerbocker to Senior Vice President and Chief Business Officer
Thursday, May 3, 2012
PDF 7.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Second Strategic Alliance With GlaxoSmithKline
Tuesday, April 17, 2012
PDF 7.4 KB Add to Briefcase
View Summary Five Prime Therapeutics Confirms Appointment of Lewis T. “Rusty” Williams as CEO and Announces the Appointment of Brian Atwood as Chairman of the Board
Monday, February 6, 2012
PDF 7.7 KB Add to Briefcase
View Summary FIVE PRIME THERAPEUTICS PROVIDES AN UPDATE ON ITS STRATEGIC DISCOVERY COLLABORATIONS WITH PFIZER AND GLAXOSMITHKLINE
Thursday, June 16, 2011
PDF 7.2 KB Add to Briefcase
View Summary FivePrime President & CEO named one of 150 Most Influential Women in Bay Area Business
Friday, April 29, 2011
PDF 4.7 KB Add to Briefcase
View Summary Dyax Corp. and Five Prime Therapeutics, Inc. Enter Into Research Agreement for Discovery of Therapeutic Antibodies
Tuesday, April 26, 2011
PDF 48.9 KB Add to Briefcase
View Summary Five Prime Therapeutics, Inc. to Present at Future Leaders in the Biotech Industry Conference in New York
Thursday, April 7, 2011
PDF 6.1 KB Add to Briefcase
View Summary HUMAN GENOME SCIENCES AND FIVEPRIME THERAPEUTICS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR NOVEL ANTI-CANCER DRUG
Wednesday, March 16, 2011
PDF 13.0 KB Add to Briefcase
View Summary Five Prime Therapeutics, Inc. to Present at Cowen and Company 31st Annual Health Care Conference
Monday, February 28, 2011
PDF 5.8 KB Add to Briefcase
View Summary Five Prime Therapeutics, Inc. to Present at the 13th Annual BIO CEO & Investor Conference
Thursday, February 10, 2011
PDF 5.7 KB Add to Briefcase
Showing 141-160 of 181 Page: 1 ... 4 5 6 7 8 9 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
35.24
Change (%)
-0.50
Volume
166,565

Data as of 4:00 PM ET on Thursday, September 21, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.